Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 4/20 | 0.71 |
| ▸ | HTR2C | P28335 | 6/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16338324 | 0.99 | PRKDC (0.69) | PRKDCHTR2CIRAK4ITGA2BADRB1 | |
| SCHEMBL27145733 | 0.85 | PRKDC (0.74) | PRKDCKDM4EUSP2ALDH1A1HTT | |
| SCHEMBL15174176 | 0.83 | PRKDC (0.71) | PRKDCALDH1A1HTR3A | |
| SCHEMBL31060462 | 0.83 | PRKDC (0.71) | PRKDCKDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL4544196 | 0.83 | PRKDC (1.00) | PRKDCMTOR | |
| SCHEMBL15174083 | 0.82 | PRKDC (0.58) | PRKDCKDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL15175579 | 0.82 | PRKDC (0.58) | PRKDCKDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL16338755 | 0.80 | PRKDC (0.62) | PRKDCKDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL15174332 | 0.80 | PRKDC (0.66) | PRKDCKDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL15173852 | 0.80 | PRKDC (0.66) | PRKDCKDM4EALDH1A1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062460-A1 | METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS | THERIPION, INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-12509501-B2 | Polynucleotides encoding APOA-1 fusion polypeptides | THERIPION, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250206806-A1 | POLYNUCLEOTIDES ENCODING APOA-1 FUSION POLYPEPTIDES | THERIPION, INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-12331102-B2 | APOA-1 fusion polypeptides and related compositions | THERIPION, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2024247267-A1 | ACCESS POINT, WIRELESS TERMINAL DEVICE, AND WIRELESS COMMUNICATION METHOD | 日本電信電話株式会社 | 2024-12-05 | — | — | WO | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230024372-A1 | POLYNUCLEOTIDES ENCODING APOA1-RNASE FUSION POLYPEPTIDES | THERIPION INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11472864-B2 | Polynucleotides encoding APOA1-PON1 fusion polypeptides | THERIPION, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11395822-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9879007-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2017-05-11 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-3035935-A2 | SCREENING METHOD | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015024876-A2 | SCREENING METHOD | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
| EP-2812004-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | PRKDC 4355/4885HTR2C 4677/4885IRAK4 4021/4885 |
| US-20260062460-A1 | METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS | PON1, APOB, APOL1 | PRKDC 4292/4885HTR2C 4536/4885IRAK4 938/4885 |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | PRKDC 4306/4885HTR2C 4604/4885IRAK4 3726/4885 |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | PRKDC 1392/4885HTR2C 4648/4885IRAK4 2733/4885 |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | PRKDC 4306/4885HTR2C 4604/4885IRAK4 3726/4885 |
| US-12509501-B2 | Polynucleotides encoding APOA-1 fusion polypeptides | APOB, PON1, APOL1 | PRKDC 3478/4885HTR2C 4776/4885IRAK4 930/4885 |
| US-11395822-B2 | Methods for treating Huntington's disease | HTT, HYPK, RECQL | PRKDC 4478/4885HTR2C 821/4885IRAK4 4514/4885 |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | PRKDC 4306/4885HTR2C 4604/4885IRAK4 3726/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | PRKDC 4759/4885HTR2C 4575/4885IRAK4 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.